- 07 May 2025 17:00:32
- Source: Sharecast
Haleon plc: EMTN programme publication of listing particulars
07 May 2025: Haleon plc (the "Company" or "Haleon") today announces that, following a routine annual update, listing particulars dated 7 May 2025 regarding Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10,000,000,000 Euro Medium Term Note ("EMTN") Programme, guaranteed by the Company, have been published (the "Listing Particulars").
A copy of the Listing Particulars is available for inspection at and can be downloaded from www.haleon.com/investors/debt-investors.
Amanda Mellor
Company Secretary
Enquiries
|
Investors |
Media
|
||
|
Jo Russell |
+44 7787 392441 |
Zoë Bird |
+44 7736 746167 |
|
Rakesh Patel |
+44 7552 484646 |
Victoria Durman |
+44 7894 505730 |
|
Emma White |
+44 7823 523562 |
|
|
|
Email: investor-relations@haleon.com |
Email: corporate.media@haleon.com |
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
Disclaimer
Please note that the information contained in the Listing Particulars may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Listing Particulars) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Listing Particulars is not addressed. Prior to relying on the information contained in the Listing Particulars, you must ascertain from the Listing Particulars whether or not you are part of the intended addressees of the information contained in the Listing Particulars.
Your right to access this service is conditional upon complying with the above requirement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
